Solid dispersions enhance solubility, dissolution, and permeability of thalidomide

References

• Melchert M, List A. The thalidomide saga. Int J Biochem Cell Biol 2007;39:1489–99.
   PubMed Web of Science ®Google Scholar
• Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004;363:1802–11.
   PubMed Web of Science ®Google Scholar
• Sherbet GV. Therapeutic potential of thalidomide and its analogues in the treatment of cancer. Anticancer Res 2015;35:5767–72.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Richardson PG, Moreau P, Anderson KC. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol 2015;12:42–54.
   PubMed Web of Science ®Google Scholar
• Kumar V, Chhibber S. Thalidomide: an old drug with new action. J Chemother 2011;23:326–34.
   PubMed Web of Science ®Google Scholar
• Teo SK, Stirling DI, Zeldis JB. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov Today 2005;10:107–14.
   PubMed Web of Science ®Google Scholar
• Teo SK, Colburn WA, Tracewell WG, et al. Clinical pharmacokinetics of thalidomide. Clin Pharmacokinet 2004;43:311–27.
   PubMed Web of Science ®Google Scholar
• Eriksson T, Bjorkman S, Hoglund P. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 2001;57:365–76.
   PubMed Web of Science ®Google Scholar
• Teo SK, Scheffler MR, Kook KA, et al. Thalidomide dose proportionality assessment following single doses to healthy subjects. J Clin Pharmacol 2001;41:662–7.
   PubMed Web of Science ®Google Scholar
• Carini JP, Pavei C, Silva AP, et al. Solid state evaluation of some thalidomide raw materials. Int J Pharm 2009;372:17–23.
   PubMed Web of Science ®Google Scholar
• Allen FH, Trotter J. Crystal and molecular structure of thalidomide, N-([small alpha]-glutarimido)-phthalimide. J Chem Soc B 1971;1073–9.
   Web of Science ®Google Scholar
• Reepmeyer JC, Rhodes MO, Cox DC, Silverton JV. Characterization and crystal structure of two polymorphic forms of racemic thalidomide. J Chem Soc B 1994;2:2063–7.
   Google Scholar
• Kratz JM, Teixeira MR, Ferronato K, et al. Preparation, characterization, and in vitro intestinal permeability evaluation of thalidomide-hydroxypropyl-beta-cyclodextrin complexes. AAPS PharmSciTech 2012;13:118–24.
   PubMed Web of Science ®Google Scholar
• Kale R, Tayade P, Saraf M, Juvekar A. Molecular encapsulation of thalidomide with sulfobutyl ether-7 beta-cyclodextrin for immediate release property: enhanced in vivo antitumor and antiangiogenesis efficacy in mice. Drug Dev Ind Pharm 2008;34:149–56.
   PubMed Web of Science ®Google Scholar
• Alvarez C, Calero J, Menendez JC, et al. Effects of hydroxypropyl-beta-cyclodextrin on the chemical stability and the aqueous solubility of thalidomide enantiomers. Pharmazie 2008;63:511–13.
   PubMed Web of Science ®Google Scholar
• Siefert B, Pleyer U, Muller M, et al. Influence of cyclodextrins on the in vitro corneal permeability and in vivo ocular distribution of thalidomide. J Ocul Pharmacol Ther 1999;15:429–38.
   PubMed Web of Science ®Google Scholar
• Krenn M, Gamcsik MP, Vogelsang GB, et al. Improvements in solubility and stability of thalidomide upon complexation with hydroxypropyl-beta-cyclodextrin. J Pharm Sci 1992;81:685–9.
   PubMed Web of Science ®Google Scholar
• Koch HP, Steinacker C. [Improvement in solubility and stability of thalidomide by synthesis of inclusion complexes with cyclodextrins]. Arch Pharm (Weinheim) 1988;321:371–3.
   PubMed Web of Science ®Google Scholar
• Vo CL, Park C, Lee BJ. Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs. Eur J Pharm Biopharm 2013;85:799–813.
   PubMed Web of Science ®Google Scholar
• Kumar S, Bhargava D, Thakkar A, Arora S. Drug carrier systems for solubility enhancement of BCS class II drugs: a critical review. Crit Rev Ther Drug Carrier Syst 2013;30:217–56.
   PubMed Web of Science ®Google Scholar
• Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 2007;12:1068–75.
   PubMed Web of Science ®Google Scholar
• Daravath B, Tadikonda RR, Vemula SK. Formulation and pharmacokinetics of gelucire solid dispersions of flurbiprofen. Drug Dev Ind Pharm 2015;41:1254–62.
   PubMed Web of Science ®Google Scholar
• Caon T, Kratz JM, Kuminek G, et al. Oral saquinavirmesylate solid dispersions: in vitro dissolution, Caco-2 cell model permeability and in vivo absorption studies. Powder Technol 2015;269:200–6.
   Web of Science ®Google Scholar
• Guo Y, Luo J, Tan S, et al. The applications of Vitamin E TPGS in drug delivery. Eur J Pharm Sci 2013;49:175–86.
   PubMed Web of Science ®Google Scholar
• Dahan A, Beig A, Ioffe-Dahan V, et al. The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: increased apparent solubility and drug flux through the intestinal membrane. AAPS J 2013;15:347–53.
   PubMed Web of Science ®Google Scholar
• Sinha S, Ali M, Baboota S, et al. Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir. AAPS PharmSciTech 2010;11:518–27.
   PubMed Web of Science ®Google Scholar
• Khoo SM, Porter CJ, Charman WN. The formulation of Halofantrine as either non-solubilizing PEG 6000 or solubilizing lipid based solid dispersions: physical stability and absolute bioavailability assessment. Int J Pharm 2000;205:65–78.
   PubMed Web of Science ®Google Scholar
• Zhao K, Yuan Y, Wang H, Li P, Bao Z, Li Y. Preparation and evaluation of valsartan by a novel semi-solid self-microemulsifying delivery system using Gelucire® 44/14. Drug Dev Ind Pharm 2016;ahead of print.
   Web of Science ®Google Scholar
• Shin SC, Kim J. Physicochemical characterization of solid dispersion of furosemide with TPGS. Int J Pharm 2003;251:79–84.
   PubMed Web of Science ®Google Scholar
• Araujo FA, Kelmann RG, Araujo BV, et al. Development and characterization of parenteral nanoemulsions containing thalidomide. Eur J Pharm Sci 2011;42:238–45.
   PubMed Web of Science ®Google Scholar
• Miller JM, Beig A, Carr RA, et al. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability. Mol Pharm 2012;9:2009–16.
   PubMed Web of Science ®Google Scholar
• Dhumal RS, Biradar SV, Aher S, Paradkar AR. Cefuroxime axetil solid dispersion with polyglycolized glycerides for improved stability and bioavailability. J Pharm Pharmacol 2009;61:743–51.
   PubMed Web of Science ®Google Scholar
• Avdeef A, Bendels S, Di L, et al. PAMPA-critical factors for better predictions of absorption. J Pharm Sci 2007;96:2893–909.
   PubMed Web of Science ®Google Scholar
• Powder Diffraction File (PDF) – Pattern: 19-1946. Joint Committee on Powder Diffraction Standards (JCPDS).
   Google Scholar
• Lara-Ochoa F, Perez GE, Mijangos-Santiago F. Calorimetric determinations and theoretical calculations of polymorphs of thalidomide. J MolStruct 2007;840:97–106.
   Web of Science ®Google Scholar
• Frank KJ, Rosenblatt KB, Westedt U, et al. Amorphous solid dispersion enhances permeation of poorly soluble ABT-102: true supersaturation vs. apparent solubility enhancement. Int J Pharm 2012;437:288–93.
   PubMed Web of Science ®Google Scholar
• Frank KJ, Westedt U, Rosenblatt KM, et al. The amorphous solid dispersion of the poorly soluble ABT-102 forms nano/microparticulate structures in aqueous medium: impact on solubility. Int J Nanomed 2012;7:5757–68.
   PubMed Web of Science ®Google Scholar
• Frank KJ, Westedt U, Rosenblatt KM, et al. Impact of FaSSIF on the solubility and dissolution-/permeation rate of a poorly water-soluble compound. Int J Pharm 2012;47:16–20.
   Google Scholar